Category
Antibody Therapy Cell & Gene Therapy Others Small Molecule
2025/12/18Flyer Small Molecule
PARP inhibitors are currently in the preclinical development stage, aiming to address the challenges of systemic toxicity and limited blood-brain barrier (BBB) penetration.
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial cross-border BD consulting service to encompass segments in equity investment and project incubation.
 |
Protheragen Inc. |
 |
Quick Links |
